Nuvalent Inc.
Nuvalent, Inc. Announces Election of New Directors at 2026 Annual Meeting
Summary
On June 16, 2026, Nuvalent, Inc. held its 2026 Annual Meeting of Stockholders, where shareholders elected two new Class II directors, Michael L. Meyers, M.D., Ph.D. and Ron Squarer, to serve on the Board for a three-year term. The meeting also saw the approval of the compensation paid to the Company's named executive officers on an advisory basis, and the ratification of KPMG LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026. A total of 71,190,894 shares of the Company's Class A common stock were present or represented by proxy at the meeting, representing approximately 96.80% of the Company's outstanding Class A common stock as of the record date.
Profitelligence Alerts
Get alerts for NUVL
Be first to know when Nuvalent Inc. files with the SEC.
Filing Categories
Advertisement
About Nuvalent Inc.
Nuvalent Inc. is a biopharmaceutical company dedicated to the innovative development of small molecule therapies for cancer treatment. The company's primary focus is on creating targeted solutions for patients with cancer-related resistance mutations and treatment-related adverse effects. By leveraging their expertise in medicinal chemistry and deep understanding of tumor biology, Nuvalent aims to address significant gaps in current cancer therapies, particularly where existing treatments fall short due to resistance mechanisms. The company operates in a highly specialized sector that covers oncology research and development, presenting potential game-changing approaches within the broader pharmaceutical industry. Through its commitment to research and innovation, Nuvalent collaborates with leading research institutions to push the boundaries of what is achievable in cancer treatment. Situated within an ever-evolving market, the company plays a critical role in advancing new oncological solutions that may ultimately improve the quality of life for patients globally. Founded with the mission to transform patient care, Nuvalent's asset offerings are a testament to the progressive strides being made in next-generation cancer therapeutics.
Official SEC Documents
Advertisement